Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


OTC Records Inspection Concerns Raised At FDA, CHPA Meeting

This article was originally published in The Tan Sheet

Executive Summary

Potential industry concerns regarding implementation of the FDA Modernization Act's new OTC records inspection provisions were raised during an "explor-atory" meeting between FDA and the Consumer Healthcare Products Association Sept. 15.

You may also be interested in...

FDA inspection of OTC company records expected after "time, guidance" given industry.

FDA INSPECTION OF OTC COMPANY RECORDS is expected to begin only after the agency has provided "sufficient time and guidance" to the OTC drug industry, according to a conference committee "explanatory statement" on the major FDA reform bill, the FDA Modernization Act of 1997, that passed the House and Senate Nov. 9. The bill provides FDA with new authority to inspect OTC drug facilities and records to the same extent as prescription drugs.

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts